Literature DB >> 29967001

Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma.

Brooke L Fridley1,2, Junqiang Dai3, Rama Raghavan3, Qian Li3,2, Stacey J Winham4, Xiaonan Hou5, S John Weroha5,6, Chen Wang4, Kimberly R Kalli5, Julie M Cunningham7, Kate Lawrenson8,9, Simon A Gayther9,10, Ellen L Goode4.   

Abstract

Background: Endometrioid carcinoma (EC) and clear cell carcinoma (CC) histotypes of epithelial ovarian cancer are understudied compared with the more common high-grade serous carcinomas (HGSC). We therefore sought to characterize EC and CC transcriptomes in relation to HGSC.
Methods: Following bioinformatics processing and gene abundance normalization, differential expression analysis of RNA sequence data collected on fresh-frozen tumors was completed with nonparametric statistical analysis methods (55 ECs, 19 CCs, 112 HGSCs). Association of gene expression with progression-free survival (PFS) was completed with Cox proportional hazards models. Eight additional multi-histotype expression array datasets (N = 852 patients) were used for replication.
Results: In the discovery set, tumors generally clustered together by histotype. Thirty-two protein-coding genes were differentially expressed across histotype (P < 1 × 10-10) and showed similar associations in replication datasets, including MAP2K6, KIAA1324, CDH1, ENTPD5, LAMB1, and DRAM1 Nine genes associated with PFS (P < 0.0001) showed similar associations in replication datasets. In particular, we observed shorter PFS time for CC and EC patients with high gene expression for CCNB2, CORO2A, CSNK1G1, FRMD8, LIN54, LINC00664, PDK1, and PEX6, whereas, the converse was observed for HGSC patients.Conclusions: The results suggest important histotype differences that may aid in the development of treatment options, particularly those for patients with EC or CC.Impact: We present replicated findings on transcriptomic differences and how they relate to clinical outcome for two of the rarer ovarian cancer histotypes of EC and CC, along with comparison with the common histotype of HGSC. Cancer Epidemiol Biomarkers Prev; 27(9); 1101-9. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29967001      PMCID: PMC6719542          DOI: 10.1158/1055-9965.EPI-17-0728

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  5 in total

Review 1.  Designer Self-Assembling Peptide Hydrogels to Engineer 3D Cell Microenvironments for Cell Constructs Formation and Precise Oncology Remodeling in Ovarian Cancer.

Authors:  Zehong Yang; Hongyan Xu; Xiaojun Zhao
Journal:  Adv Sci (Weinh)       Date:  2020-03-20       Impact factor: 16.806

2.  Systematic Identification of Characteristic Genes of Ovarian Clear Cell Carcinoma Compared with High-Grade Serous Carcinoma Based on RNA-Sequencing.

Authors:  Saya Nagasawa; Kazuhiro Ikeda; Kuniko Horie-Inoue; Sho Sato; Atsuo Itakura; Satoru Takeda; Kosei Hasegawa; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2019-09-04       Impact factor: 5.923

3.  Identification of Core Genes Involved in the Metastasis of Clear Cell Renal Cell Carcinoma.

Authors:  Rui Peng; Yahui Wang; Likai Mao; Fang Fang; Han Guan
Journal:  Cancer Manag Res       Date:  2020-12-30       Impact factor: 3.989

4.  Identification of ceRNA (lncRNA-miRNA-mRNA) Regulatory Network in Myocardial Fibrosis After Acute Myocardial Infarction.

Authors:  Shuo Wang; Yuying Liu; Xitian Hu; Xiaolei Zhang; Lei Xu; Yan Yang; Rubing Wu; Enmao Wang; Tianjie Lv
Journal:  Int J Gen Med       Date:  2021-12-19

5.  Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.

Authors:  Jaime I Davila; Pritha Chanana; Vivekananda Sarangi; Zachary C Fogarty; S John Weroha; Ruifeng Guo; Ellen L Goode; Yajue Huang; Chen Wang
Journal:  BMC Med Genomics       Date:  2021-06-22       Impact factor: 3.063

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.